Novo Nordisk Board Overhaul: Foundation Gains Unprecedented Control Amid Governance Concerns

Board Shakeup at Novo Nordisk

• 🎯 Novo Nordisk's top shareholder, the Novo Nordisk Foundation, forced a significant board overhaul on Friday.
• 💡 This move has resulted in the foundation gaining unprecedented control over the Danish drugmaker.

New Leadership and Governance Worries

• 👑 The foundation's chairman, Lars Rebien Sorensen, has been installed as the new Novo chair, creating a dual role.
• ⚠️ This unprecedented concentration of power has sparked protests from some investors, raising governance concerns.
• 📉 The reshuffle follows the departure of the previous board chair and independent members under pressure.

Foundation's Role and Future Test

• 🏥 The nonprofit Novo Nordisk Foundation aims to ensure the financial and strategic stability of the Novo Group and advance research.
• 📈 The foundation already held 77% of the drugmaker's voting rights, and the new board received over 90% approval.
• 🤔 Sorensen's dual role will test the foundation ownership model designed to provide stability, especially after a tumultuous period for the company.

Company Context

• 🚀 Novo Nordisk became Europe's most valuable firm due to the success of its 2021 obesity drug, Wegovy.
• 📉 The company has faced challenges recently with slowing sales and increased competition from rivals like Eli Lilly.